ATE505464T1 - Feste form von amg 706 und pharmazeutische zusammensetzungen davon - Google Patents

Feste form von amg 706 und pharmazeutische zusammensetzungen davon

Info

Publication number
ATE505464T1
ATE505464T1 AT06849937T AT06849937T ATE505464T1 AT E505464 T1 ATE505464 T1 AT E505464T1 AT 06849937 T AT06849937 T AT 06849937T AT 06849937 T AT06849937 T AT 06849937T AT E505464 T1 ATE505464 T1 AT E505464T1
Authority
AT
Austria
Prior art keywords
amg
amorphous
drug substance
crystallization inhibitor
pharmaceutical compositions
Prior art date
Application number
AT06849937T
Other languages
English (en)
Inventor
Belle B Liu
Gonzalo Alva
Nina Cauchon
Seshadri Neervannan
Pengzu Zhou
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE505464T1 publication Critical patent/ATE505464T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06849937T 2005-12-23 2006-12-08 Feste form von amg 706 und pharmazeutische zusammensetzungen davon ATE505464T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75390905P 2005-12-23 2005-12-23
US11/636,183 US20080108664A1 (en) 2005-12-23 2006-12-07 Solid-state form of AMG 706 and pharmaceutical compositions thereof
PCT/US2006/047238 WO2007087026A2 (en) 2005-12-23 2006-12-08 Solid-state form of amg 706 and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
ATE505464T1 true ATE505464T1 (de) 2011-04-15

Family

ID=38198261

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06849937T ATE505464T1 (de) 2005-12-23 2006-12-08 Feste form von amg 706 und pharmazeutische zusammensetzungen davon

Country Status (8)

Country Link
US (3) US20080108664A1 (de)
EP (1) EP2013198B1 (de)
JP (1) JP5830216B2 (de)
AT (1) ATE505464T1 (de)
AU (1) AU2006336563B2 (de)
CA (1) CA2633077C (de)
DE (1) DE602006021348D1 (de)
WO (1) WO2007087026A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102026634B (zh) 2008-04-10 2014-01-22 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
EP2288383A1 (de) * 2008-05-14 2011-03-02 Amgen, Inc Kombinationen von vegf(r)-inhibitoren und hepatozyten-wachstumsfaktor (c-met)-inhibitoren zur behandlung von krebs
US20100003319A1 (en) * 2008-07-02 2010-01-07 Glenmark Generics Ltd. Raloxifene immediate release tablets
EP2545174B1 (de) * 2010-03-11 2015-11-11 Health Research, Inc. Verfahren und zusammensetzungen mit fc-fusionsproteinen zur verstärkung von immunreaktionen
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2739252A4 (de) 2011-08-05 2015-08-12 Forsight Vision4 Inc Abgabe kleiner moleküle über eine implantierbare therapeutische vorrichtung
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
EP3177289A4 (de) 2014-08-08 2018-03-21 Forsight Vision4, Inc. Stabile und lösliche formulierungen von rezeptortyrosinkinaseinhibitoren und verfahren zur herstellung davon

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2762522B2 (ja) 1989-03-06 1998-06-04 藤沢薬品工業株式会社 血管新生阻害剤
CA2011116C (en) 1989-03-06 1999-11-16 Murray A. Kaplan Lyophilized bmy-28142 dihydrochloride for parenteral use
JPH02279769A (ja) * 1989-04-20 1990-11-15 Kao Corp ブリリアントカーミン６ｂナトリウム塩の無定形物、その製造法及びこれを含有する化粧料
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
CA2222811C (en) * 1995-06-01 2008-09-30 G.D. Searle & Co. Stabilized solid dispersions of misoprostol
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US6582921B2 (en) * 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
JP2002505330A (ja) 1998-03-04 2002-02-19 ブリストル−マイヤーズ スクイブ カンパニー ヘテロシクロ−置換イミダゾピラジン・たんぱくチロシンキナーゼ抑制剤
NZ508815A (en) 1998-05-29 2005-02-25 Sugen Inc Pyrrole substituted 2-indolinone protein kinase inhibitors
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
CA2336848A1 (en) 1998-07-10 2000-01-20 Merck & Co., Inc. Novel angiogenesis inhibitors
JP2002523459A (ja) 1998-08-31 2002-07-30 メルク エンド カムパニー インコーポレーテッド 新規血管形成阻害剤
DE60028740T2 (de) 1999-03-30 2007-05-24 Novartis Ag Phthalazinderivate zur behandlung von entzündlichen erkrankungen
EE05330B1 (et) 1999-11-05 2010-08-16 Astrazeneca Ab Kinasoliini derivaadid kui VEGF-i inhibiitorid
JP5336686B2 (ja) 1999-11-24 2013-11-06 スージェン， インク． 遊離酸または遊離塩基としてイオン化可能な医薬品のための処方
ES2324981T3 (es) 2000-12-21 2009-08-21 Smithkline Beecham Corporation Pirimidinaminas como moduladores de la angiogenesis.
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US20030232871A1 (en) * 2002-03-15 2003-12-18 Sheikh Ahmad Y. Crystalline parecoxib sodium
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases

Also Published As

Publication number Publication date
DE602006021348D1 (de) 2011-05-26
JP2009527460A (ja) 2009-07-30
WO2007087026A9 (en) 2009-01-08
JP5830216B2 (ja) 2015-12-09
CA2633077C (en) 2012-02-21
CA2633077A1 (en) 2007-08-02
US20130317227A1 (en) 2013-11-28
EP2013198B1 (de) 2011-04-13
AU2006336563A1 (en) 2007-08-02
WO2007087026A3 (en) 2007-09-13
WO2007087026A2 (en) 2007-08-02
AU2006336563B2 (en) 2010-08-26
US8648199B2 (en) 2014-02-11
US20080108664A1 (en) 2008-05-08
US20100331548A1 (en) 2010-12-30
EP2013198A2 (de) 2009-01-14

Similar Documents

Publication Publication Date Title
ATE505464T1 (de) Feste form von amg 706 und pharmazeutische zusammensetzungen davon
DK1150959T3 (da) Faststoftilstandsform af Celecoxib, der har foröget biotilgængelighed
CY1118179T1 (el) Φαρμακευτικη συνθεση
DE60118547D1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
BRPI0507628A (pt) composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
MX344865B (es) Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1(2-tiazolil)-1,8-naftiridina-3-ca rboxilico para el tratamiento de ciertos padecimientos hematologicos.
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
DE602006017965D1 (de) Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
ME00181B (me) Farmaceutske formulacije inhibitora renin-angiotenzin sistema (ras) i njihova primjena
ATE508114T1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
WO2007128086A3 (en) Novel viral replication inhibitor
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
MY128971A (en) Solid-state form of celecoxib having enhanced bioavailability
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
EP1844779A3 (de) Tergurid/Protergurid zur Behandlung von chronischen Schmerzen (z.B. Migräne)
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
ATE489380T1 (de) Hydratformen von amg706
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
ATE468130T1 (de) Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie
EA200901145A1 (ru) Применение рибофлавина в лечении гипертензии
SE0203817D0 (sv) New composition

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties